China Money Network
Login
Join

GTJA Leads $45M Round In Chinese Antibody Drug Developer Akeso

  • August 29, 2017 — 12:22 CST

This Data Is Locked!

This area is available only to Subscribers.

The GTJA Investment Group has led a RMB300 million (US$45 million) series B round in Akeso Biopharma, a Chinese innovative biotechnology company. Shenzhen Capital Group... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Join

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?

Login
Related Topics:

Related Data: